Science Explorer Back to mapMap
Discussion
Company · Kurume · Japan

BrightPath Biotherapeutics (Japan)

brightpathbio.com/englishROR OpenAlex
Research works
12
▲ 159% vs 2018-21
Citations
61
5.0 per fractional work
Top-10% rate
8.3%
all institutions 10.0%
Open access
57%
world 40%
International
3%
world 18%
BrightPath Biotherapeutics (Japan)

Not ranked overall: BrightPath Biotherapeutics (Japan) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does BrightPath Biotherapeutics (Japan) work in?

In all years, 53% of research at BrightPath Biotherapeutics (Japan) is in Life Sciences, 39% in Health Sciences. Its largest fields are Medicine (38%), Biochemistry, Genetics and Molecular Biology (29%), Immunology and Microbiology (23%). It does 2.0× the world's share of Life Sciences.

Life Sciences: 6 fractional works · 52.6% of its workBiochemistry, Genetics and Molecular Biology: 4 fractional works · 29.5% of its workPhysiology: 2 fractional works · 13.6% of its workMolecular Biology: 2 fractional works · 12.3% of its workBiotechnology: 0 fractional works · 2.7% of its workCell Biology: 0 fractional works · 0.9% of its workImmunology and Microbiology: 3 fractional works · 23.2% of its workImmunology: 3 fractional works · 23.2% of its workHealth Sciences: 5 fractional works · 38.7% of its workMedicine: 5 fractional works · 38.3% of its workOncology: 3 fractional works · 26.9% of its workRadiology, Nuclear Medicine and Imaging: 1 fractional works · 8.8% of its workGenetics: 0 fractional works · 1.4% of its workRheumatology: 0 fractional works · 0.9% of its workPharmacology: 0 fractional works · 0.4% of its workHealth Professions: 0 fractional works · 0.4% of its workMedical Laboratory Technology: 0 fractional works · 0.4% of its workPhysical Sciences: 1 fractional works · 8.2% of its workChemistry: 1 fractional works · 4.6% of its workOrganic Chemistry: 0 fractional works · 4.1% of its workSpectroscopy: 0 fractional works · 0.6% of its workMaterials Science: 0 fractional works · 2.7% of its workBiomaterials: 0 fractional works · 2.7% of its workEngineering: 0 fractional works · 0.9% of its workBiomedical Engineering: 0 fractional works · 0.9% of its workSocial Sciences: 0 fractional works · 0.4% of its workPsychology: 0 fractional works · 0.4% of its workSocial Psychology: 0 fractional works · 0.4% of its workALL ITS WORKBrightPathBiotherapeutics…12fractional works, all years
Life Sciences53%Physical Sciences8%Health Sciences39%Social Sciences0%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 8 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology429.5%
    2. Immunology and Microbiology323.2%
    1. Medicine538.3%
    2. Health Professions00.4%
    1. Chemistry14.6%
    2. Materials Science02.7%
    3. Engineering00.9%
    1. Psychology00.4%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Who are the top researchers at BrightPath Biotherapeutics (Japan)?

Ranked on the quality score, Yuji Mishima lead among researchers whose main affiliation is BrightPath Biotherapeutics (Japan).

  1. 1 Yuji Mishima Japan · #3,689,516 worldwide 53 citations · 19 works
All ranked researchers at BrightPath Biotherapeutics (Japan)

What are the most cited papers from BrightPath Biotherapeutics (Japan)?

The most cited paper from BrightPath Biotherapeutics (Japan) is "Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma" (Diwakar Davar, Hong Wang, Joë-Marc Chauvin et al., 2018), with 85 citations. Next come "Autologous antigen-presenting cells efficiently expand piggyBac transposon CAR-T cells with predominant memory phenotype" (33) and "Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response" (28).

Most cited papers
#PaperReleasedCitations
1 Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma Diwakar Davar, Hong Wang, Joë-Marc Chauvin et al. · Journal of Clinical Oncology Open access 25 Oct 2018 85
2 Autologous antigen-presenting cells efficiently expand piggyBac transposon CAR-T cells with predominant memory phenotype Kayoko Nakamura, Shigeki Yagyu, Shogo Hirota et al. · Molecular Therapy — Methods & Clinical Development Open access 23 Mar 2021 33
3 Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response Hiroaki Mashima, Rong Zhang, Tsuyoshi Kobayashi et al. · OncoImmunology Open access 2020 28
4 Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations Susumu Iiizumi, Junya Ohtake, Naoko Murakami et al. · Cancers Open access 24 Feb 2019 28
5 Enhancing Mass spectrometry-based tumor immunopeptide identification: machine learning filter leveraging HLA binding affinity, aliphatic index and retention time deviation Feifei Wei, Taku Kouro, Yuko Nakamura et al. · Computational and Structural Biotechnology Journal Open access 3 Feb 2024 18
All 9 most cited papers, with filters and sorting

Which research topics does BrightPath Biotherapeutics (Japan) publish most on?

By volume in 2022-now: CAR-T cell therapy research, Adenosine and Purinergic Signaling, Immune Cell Function and Interaction and Cancer Immunotherapy and Biomarkers.

CAR-T cell therapy resea…2CAR-T cell therapy research: 2 fractional worksAdenosine and Purinergic Signaling: 1 fractional worksImmune Cell Function and Interaction: 1 fractional worksCancer Immunotherapy and Biomarkers: 0 fractional worksImmunotherapy and Immune Responses: 0 fractional worksClick Chemistry and Applications: 0 fractional worksCancer Research and Treatments: 0 fractional worksGalectins and Cancer Biology: 0 fractional worksMonoclonal and Polyclonal Antibodies Research: 0 fractional worksvaccines and immunoinformatics approaches: 0 fractional works
OncologyPhysiologyImmunologyOrganic Chemistry3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 CAR-T cell therapy research Oncology 2 works
  2. 2 Adenosine and Purinergic Signaling Physiology 1 works
  3. 3 Immune Cell Function and Interaction Immunology 1 works
  4. 4 Cancer Immunotherapy and Biomarkers Oncology 0 works
  5. 5 Immunotherapy and Immune Responses Immunology 0 works
  6. 6 Click Chemistry and Applications Organic Chemistry 0 works
  7. 7 Cancer Research and Treatments Biotechnology 0 works
  8. 8 Galectins and Cancer Biology Immunology 0 works
  9. 9 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 0 works
  10. 10 vaccines and immunoinformatics approaches Molecular Biology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available56.9%not open43.1%

World: 40% of research is openly available.

with international co-authors2.9%domestic only97.1%

World: 18% is written across borders.

How has BrightPath Biotherapeutics (Japan)'s research output changed?

Output in 2022-2025 was 159% higher than in 2018-2021.

still counting1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Kurume

All research institutions in Kurume

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about BrightPath Biotherapeutics (Japan). Posts are plain text and can be reported.